Linagliptin Fmk

Linagliptin, the active ingredient in Linagliptin Fmk, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It selectively inhibits the DPP‑4 enzyme, increasing incretin levels and improving glycemic control in adults with type 2 diabetes.

GNH USA supplies Linagliptin Fmk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and the product conforms to European Union marketing authorization standards.

Linagliptin is a DPP‑4 inhibitor used to manage hyperglycaemia in type 2 diabetes. - Type 2 diabetes mellitus (monotherapy): reduces HbA1c as a single oral agent. - Type 2 diabetes mellitus (combination therapy): enhances glucose control when added to metformin or other oral antidiabetics. - Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise in achieving target blood glucose levels.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate pain. - Dizziness: occasional light‑headed sensation. - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Back pain: occasional musculoskeletal discomfort. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Hypoglycaemia (when combined with sulfonylureas or insulin): symptoms of low blood sugar. - Bullous pemphigoid: blistering skin disorder. - Stevens‑Johnson syndrome: rare severe skin reaction.

Linagliptin should be used with clinical monitoring in specific patient groups. - Renal impairment: assess kidney function; dose adjustment may be required. - Hepatic impairment: monitor liver enzymes regularly. - Concomitant sulfonylureas or insulin: watch for signs of hypoglycaemia. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Elderly patients: increased vigilance for adverse reactions. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Linagliptin may interact with several medicines that affect its plasma levels or glycaemic response. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Strong P‑gp inducers (e.g., rifampin): may reduce efficacy. - Sulfonylureas or insulin: heightened risk of hypoglycaemia. Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium. - Diuretics: watch for electrolyte disturbances. - Warfarin: periodic INR checks are advisable.